Tickr
Home Explore Daily Brief Market Watchlists Portfolio
Research
Catalysts Signal Factory Screener Market News Event Calendar Valuation Plot Heat Map Top Investors Industry Trends Options
AI Assistant Notifications Account
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. (PLX) Stock Ticker

AMEX: PLX · Healthcare · Biotechnology
$2.72-1.09%
USD · as of 2026-09-28 · market cap $219.2M
Open PLX in TickrDownload for iPhone

PLX right now

Growing revenue 30% a year on 69% gross margins.
Options expect by Oct 6±8.8%
Options expect by Oct 29±18.2%
Priced in for Nov 12 earnings±22.0%
IV rank (30-day)24% · cheap
From Tickr's live models · 2026-09-29. Not investment advice.

Market factors today

Tickr 500 vs S&P 500+0.49%+1.0% MTD
Momentum L/S+1.35%+15.1% MTD
High-beta momo L/S+1.46%+22.2% MTD
Rate sensitivity L/S+1.91%+6.9% MTD
Oil sensitivity L/S-2.54%-5.3% MTD
Unprofitable tech-1.43%+3.7% MTD

Unlock the full PLX picture

🔒 Implied move chart & probabilities
🔒 Live options flow
🔒 AI analysis & chat on PLX
🔒 Catalysts & earnings
🔒 Strategy Lab
🔒 Financials & estimates
Start your 7-day free trial

About Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.

PLX stock facts

Ticker symbolPLX
ExchangeNew York Stock Exchange Arca
SectorHealthcare
IndustryBiotechnology
Market cap$219.2M
CEODror Bashan
Employees226
HeadquartersHackensack, NJ, US
IPO date1998-05-15
Websitewww.protalix.com

What you can see for PLX on Tickr

Live PLX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the PLX report.

Rankings

Largest Healthcare companiesLargest companies by market cap

FAQ

What is the ticker symbol for Protalix BioTherapeutics, Inc.?

The ticker symbol for Protalix BioTherapeutics, Inc. is PLX, listed on the New York Stock Exchange Arca.

What is PLX?

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also…

HomeExploreMarketLists
All pages